Health Care · Surgical & Medical Instruments & Apparatus

CERS CERUS CORP SEC Filings & Insider Trading Activity 2026

company
CIK 1020214125 filings
Russell 2000

CERS at a glance

CERUS CORP (CERS, SEC CIK 1020214) filed its latest 10-K annual report on March 2, 2026, a 10-Q quarterly report on November 2, 2026, an 8-K current report on November 2, 2026 and Form 4 insider filings as recently as August 17, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), CERUS CORP (CERS) reported revenue of $233.8 million (up 16.1% from FY2024) and a net loss of $15.6 million. Diluted EPS was -$0.08.
  • As of September 30, 2026, 27 institutional investment managers tracked by SignalX reported holding CERUS CORP (CERS) shares worth $188.7 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Jensen Chrystal on August 17, 2026 of 30,000 shares at $2.98 per share.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$233.8M
+16.1% vs prior year
Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
27 funds
$188.7M · +0 vs prior quarter
Latest 8-K
Nov 2, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Revenue $64.018M, up $3.781M YoY, driven by platelet kits, IFC sales and EMEA LED illuminators
  • Product gross margin 52% vs 53% YoY, pressured by foreign exchange, inventory costs and tariffs
  • Product revenue $57.714M, up $5.016M, while government contract revenue fell $1.235M to $6.304M
  • Cash, investments and restricted cash $57.734M vs $83.518M at December 31, 2025
  • Near-term headwinds: tariffs, conflicts, supply-chain disruption and potential reductions or delays in BARDA funding

Risk Factors

  • New regulatory risk: EU EUDAMED modules become mandatory May 28, 2026, increasing compliance costs
  • BARDA funding risk: 2016 Agreement options discontinued, while 2024 Agreement potential funding increased to $209.0 million
  • Regulatory approval risk: ANSM review continues for the red blood cell system’s MDR application after prior closure
  • Market risk: U.S. platelet shortages may reduce demand for INTERCEPT-treated products despite safety-compliance options
  • Customer concentration risk: American Red Cross represents the largest single portion of U.S. blood collection market

AI summary of the CERS 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 2, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Cerus announced Q3 2026 financial results for the quarter ended September 30, 2026
  • Detailed financial results and management commentary appear in Exhibit 99.1, the accompanying earnings release

Item EX-99.1: Item EX-99.1

  • Q3 revenue $64.0M, up 6%, with product revenue $57.7M, up 10%, supporting continued commercial growth
  • IFC demand surged approximately 80%, while U.S. IFC sales reached $5.6M versus $3.9M
Filed Jul 30, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Q2 product revenue $57.4M, up 10% YoY; total revenue $63.3M, up 5%, despite government contract revenue declining 24%
  • IFC demand increased approximately 20%; U.S. IFC sales reached $6.7M, up from $5.6M

Item 2.02: Results of Operations and Financial Condition

  • Cerus announced second-quarter 2026 financial results for the period ended June 30, 2026
  • Press release provides the substantive revenue, earnings, cash-flow and outlook details for investor review
Filed Jul 10, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • William Greenman transitioned from CEO to Executive Chairman effective July 1, 2026, reducing his operating role while preserving board leadership
  • Executive Chairman term runs through May 31, 2027, unless ended or extended earlier by agreement

AI summaries of CERS 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for CERS

Don't miss the next CERS filing

  • Alerts as it files. A push when CERS files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut CERS, by share count.
  • Ask anything. An AI agent that reads every CERS filing and answers with sources.

CERS alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Jensen ChrystalSellAug 17, 2026$2.98
Jayaraman Vivek KSellJul 16, 2026$3.16
Jayaraman Vivek KAJul 1, 2026-
Jayaraman Vivek KAJul 1, 2026-
Green Kevin DennisSellJun 30, 2026$2.94
Green Kevin DennisAJun 30, 2026-
Jayaraman Vivek KSellJun 30, 2026$2.94
Jensen ChrystalSellJun 30, 2026$2.94

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$201.3M$233.8M
Operating Income--$14.2M-$8.7M
Net Income-$37.5M-$20.9M-$15.6M
Op. Margin--7.1%-3.7%
Net Margin--10.4%-6.7%
Balance Sheet
Total Assets-$200.9M$221.9M
Equity$52.6M$56.1M$64.2M
ROE-71.2%-37.3%-24.3%
Per Share
EPS-$-0.11$-0.08
Cash Flow
Operating CF-$43.2M$11.4M$4.8M
CapEx$4.6M$2.8M$3.7M

Source: XBRL data in CERUS CORP (CERS)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate CERS share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
CERS shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202627$188.7M
Q2 202627$234.7M
Q1 202626$135.1M
Q4 202525$155.3M
Q3 202525$121.5M
Q2 202525$106.7M
Q1 202526$80.7M
Q4 202421$73.8M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 202 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

CERS filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
8-KNov 2, 2026Analysis-
10-QNov 2, 2026Analysis
4Aug 17, 2026--
10-QJul 30, 2026Analysis
8-KJul 30, 2026Analysis-
4Jul 20, 2026--
8-KJul 10, 2026Analysis-
4Jul 2, 2026--
4Jul 2, 2026--
4Jul 2, 2026--
4Jun 11, 2026--
8-KJun 8, 2026Analysis
8-KJun 3, 2026Analysis
4Jun 2, 2026-
4Jun 2, 2026-
4Jun 2, 2026-
4Jun 2, 2026-
4Jun 2, 2026-
4Jun 2, 2026-
4Jun 2, 2026-
4May 5, 2026--
8-KApr 30, 2026Analysis-
10-QApr 30, 2026Analysis
8-KApr 21, 2026Analysis-
4Apr 3, 2026--

Related Health Care companies

All Health Care →

CERS SEC filings: frequently asked questions

Which institutions hold CERS stock?

As of September 30, 2026, the largest CERUS CORP (CERS) holders among the 13F filers tracked by SignalX were BlackRock ($51.4 million), ARK Investment Management ($48.8 million), Vanguard Capital Management LLC ($20.2 million), State Street Corp ($12.1 million), D.E. Shaw & Co ($10.9 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was CERS's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), CERUS CORP (CERS) reported revenue of $233.8 million (up 16.1% from FY2024) and a net loss of $15.6 million. Diluted EPS was -$0.08. The figures come from the XBRL data in the 10-K.

What did CERS report in its latest 8-K?

CERUS CORP (CERS) filed an 8-K on November 2, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Cerus announced Q3 2026 financial results for the quarter ended September 30, 2026.

What are the latest CERS SEC filings?

CERUS CORP (CERS) filed its latest 10-K annual report on March 2, 2026, a 10-Q quarterly report on November 2, 2026, an 8-K current report on November 2, 2026 and a Form 4 insider filing on August 17, 2026.

What is CERS's SEC CIK number?

CERUS CORP (CERS)'s SEC Central Index Key (CIK) is 1020214. EDGAR lists every CERS filing under that number.

Ask anything about CERS

The research agent reads CERS's filings, financials, insider trades and 13F holders, then answers with sources.